Negative regulatory effects of Mnk kinases in the generation of chemotherapy-induced antileukemic responses

Molecular Pharmacology

Volumn 78, Issue 4, 2010, Pages 778-784

  Altman, Jessica K ^a   Glaser, Heather ^a   Sassano, Antonella ^a   Joshi, Sonali ^a   Ueda, Takeshi ^b   Watanabe Fukunaga, Rie ^c   Fukunaga, Rikiro ^c   Tallman, Martin S ^a   Platanias, Leonidas C ^a  

^a NORTHWESTERN UNIVERSITY   (United States)

^b PRINCESS MARGARET HOSPITAL   (Canada)

^c KYOTO UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CGP 57380; CYTARABINE; INITIATION FACTOR 4E; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE INHIBITOR; MITOGEN ACTIVATED PROTEIN KINASE INTERACTING KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE INTERACTING KINASE 2; N 3 (4 FLUOROPHENYL) 1H PYRAZOLO[3,4 D]PYRIMIDINE 3,4 DIAMINE; SMALL INTERFERING RNA; UNCLASSIFIED DRUG; ANTINEOPLASTIC ANTIMETABOLITE; MKNK1 PROTEIN, MOUSE; MKNK2 PROTEIN, MOUSE; PROTEIN SERINE THREONINE KINASE;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; DRUG EFFECT; DRUG POTENTIATION; DRUG RESPONSE; ENZYME ACTIVATION; ENZYME INHIBITION; ENZYME PHOSPHORYLATION; HUMAN; HUMAN CELL; IMMUNOBLOTTING; PRIORITY JOURNAL; ANIMAL; ANTAGONISTS AND INHIBITORS; CELL CULTURE; COMPARATIVE STUDY; DRUG EFFECTS; DRUG RESISTANCE; ENZYMOLOGY; K562 CELL LINE; LEUKEMIA; MOUSE; PATHOLOGY; PHYSIOLOGY; TRANSFORMED CELL LINE; U937 CELL LINE;

ANIMALS; ANTIMETABOLITES, ANTINEOPLASTIC; CELL LINE, TRANSFORMED; CELLS, CULTURED; CYTARABINE; DRUG RESISTANCE, NEOPLASM; HUMANS; K562 CELLS; LEUKEMIA; MICE; PROTEIN-SERINE-THREONINE KINASES; U937 CELLS;

EID: 77957229186     PISSN: 0026895X     EISSN: 15210111     Source Type: Journal    
DOI: 10.1124/mol.110.064642     Document Type: Article

References (41)

1. Altman JK and Platanias LC (2008) Exploiting the mammalian target of rapamycin pathway in hematologic malignancies. Curr Opin Hematol 15:88-94. (Pubitemid 351323147)
2. Altman JK, Yoon P, Katsoulidis E, Kroczynska B, Sassano A, Redig AJ, Glaser H, Jordan A, Tallman MS, Hay N, et al. (2008) Regulatory effects of mammalian target of rapamycin-mediated signals in the generation of arsenic trioxide responses. J Biol Chem 283:1992-2001.
3. Assouline S, Culjkovic B, Cocolakis E, Rousseau C, Beslu N, Amri A, Caplan S, Leber B, Roy DC, Miller WH Jr., and Borden KL (2009) Molecular targeting of the oncogene eIF4E in acute myeloid leukemia (AML): a proof-of-principle clinical trial with ribavirin. Blood 114:257-260.
4. Bhaskar PT and Hay N (2007) The two TORCs and Akt. Dev Cell 12:487-502.
5. Bonneau AM and Sonenberg N (1987) Involvement of the 24-kDa cap-binding protein in regulation of protein synthesis in mitosis. J Biol Chem 262:11134-11139.
6. Büchner T, Berdel WE, Schoch C, Haferlach T, Serve HL, Kienast J, Schnittger S, Kern W, Tchinda J, Reichle A, et al. (2006) Double induction containing either two courses or one course of high-dose cytarabine plus mitoxantrone and postremission therapy by either autologous stem-cell transplantation or by prolonged maintenance for acute myeloid leukemia. J Clin Oncol 24:2480-2489.
7. Buxadé M, Morrice N, Krebs DL, and Proud CG (2008) The PSF.p54nrb complex is a novel Mnk substrate that binds the mRNA for tumor necrosis factor alpha. J Biol Chem 283:57-65.
8. Buxadé M, Parra JL, Rousseau S, Shpiro N, Marquez R, Morrice N, Bain J, Espel E, and Proud CG (2005) The Mnks are novel components in the control of TNF alpha biosynthesis and phosphorylate and regulate hnRNP A1. Immunity 23:177-189.
9. Dolniak B, Katsoulidis E, Carayol N, Altman JK, Redig AJ, Tallman MS, Ueda T, Watanabe-Fukunaga R, Fukunaga R, and Platanias LC (2008) Regulation of arsenic trioxide-induced cellular responses by Mnk1 and Mnk2. J Biol Chem 283:12034-12042.
10. Farag SS, Ruppert AS, Mrózek K, Mayer RJ, Stone RM, Carroll AJ, Powell BL, Moore JO, Pettenati MJ, Koduru PR, et al. (2005) Outcome of induction and postremission therapy in younger adults with acute myeloid leukemia with normal karyotype: a cancer and leukemia group B study. J Clin Oncol 23:482-493. (Pubitemid 46224225)
11. Fukunaga R and Hunter T (1997) MNK1, a new MAP kinase-activated protein kinase, isolated by a novel expression screening method for identifying protein kinase substrates. EMBO J 16:1921-1933.
12. Giafis N, Katsoulidis E, Sassano A, Tallman MS, Higgins LS, Nebreda AR, Davis RJ, and Platanias LC (2006) Role of the p38 mitogen-activated protein kinase pathway in the generation of arsenic trioxide-dependent cellular responses. Cancer Res 66:6763-6771.
13. Gilliland DG and Tallman MS (2002) Focus on acute leukemias. Cancer Cell 1:417-420.
14. Guil S, Long JC, and Cáceres JF (2006) hnRNP A1 relocalization to the stress granules reflects a role in the stress response. Mol Cell Biol 26:5744-5758.
15. Hay N (2005) The Akt-mTOR tango and its relevance to cancer. Cancer Cell 8:179-183.
16. Herzig RH, Lazarus HM, Wolff SN, Phillips GL, and Herzig GP (1985) High-dose cytosine arabinoside therapy with and without anthracycline antibiotics for remission reinduction of acute nonlymphoblastic leukemia. J Clin Oncol 3:992-997.
17. Kannan-Thulasiraman P, Katsoulidis E, Tallman MS, Arthur JS, and Platanias LC (2006) Activation of the mitogen- and stress-activated kinase 1 by arsenic trioxide. J Biol Chem 281:22446-22452. (Pubitemid 44242273)
18. Knauf U, Tschopp C, and Gram H (2001) Negative regulation of protein translation by mitogen-activated protein kinase-interacting kinases 1 and 2. Mol Cell Biol 21:5500-5511. (Pubitemid 32702454)
19. Lekmine F, Uddin S, Sassano A, Parmar S, Brachmann SM, Majchrzak B, Sonenberg N, Hay N, Fish EN, and Platanias LC (2003) Activation of the p70 S6 kinase and phosphorylation of the 4E-BP1 repressor of mRNA translation by type I interferons. J Biol Chem 278:27772-27780.
20. Martelli AM, Evangelisti C, Chiarini F, Grimaldi C, Manzoli L, and McCubrey JA (2009) Targeting the PI3K/AKT/mTOR signaling network in acute myelogenous leukemia. Expert Opin Investig Drugs 18:1333-1349.
21. Mayeda A and Krainer AR (1992) Regulation of alternative pre-mRNA splicing by hnRNP A1 and splicing factor SF2. Cell 68:365-375.
22. Platanias LC (2003) Map kinase signaling pathways and hematologic malignancies. Blood 101:4667-4679. (Pubitemid 36857719)
23. Platanias LC (2005) Mechanisms of type-I- and type-II-interferon-mediated signalling. Nat Rev Immunol 5:375-386.
24. Platanias LC (2009) Biological responses to arsenic compounds. J Biol Chem 284:18583-18587.
25. Pyronnet S, Dostie J, and Sonenberg N (2001) Suppression of cap-dependent translation in mitosis. Genes Dev 15:2083-2093.
26. Raman M, Chen W, and Cobb MH (2007) Differential regulation and properties of MAPKs. Oncogene 26:3100-3112.
27. Récher C, Dos Santos C, Demur C, and Payrastre B (2005) mTOR, a new therapeutic target in acute myeloid leukemia. Cell Cycle 4:1540-1549.
28. Scheper GC, Morrice NA, Kleijn M, and Proud CG (2001) The mitogen-activated protein kinase signal-integrating kinase Mnk2 is a eukaryotic initiation factor 4E kinase with high levels of basal activity in mammalian cells. Mol Cell Biol 21:743-754.
29. Shav-Tal Y and Zipori D (2002) PSF and p54(nrb)/NonO-multi-functional nuclear proteins. FEBS Lett 531:109-114.
30. Shenberger JS, Zhang L, Hughlock MK, Ueda T, Watanabe-Fukunaga R, and Fukunaga R (2007) Roles of mitogen-activated protein kinase signal-integrating kinases 1 and 2 in oxidant-mediated eIF4E phosphorylation. Int J Biochem Cell Biol 39:1828-1842.
31. Takei N, Kawamura M, Hara K, Yonezawa K, and Nawa H (2001) Brain-derived neurotrophic factor enhances neuronal translation by activating multiple initiation processes: comparison with the effects of insulin. J Biol Chem 276:42818-42825.
32. Tamburini J, Green AS, Chapuis N, Bardet V, Lacombe C, Mayeux P, and Bouscary D (2009) Targeting translation in acute myeloid leukemia: a new paradigm for therapy? Cell Cycle 8:3893-3899.
33. Topisirovic I, Guzman ML, McConnell MJ, Licht JD, Culjkovic B, Neering SJ, Jordan CT, and Borden KL (2003) Aberrant eukaryotic translation initiation factor 4E-dependent mRNA transport impedes hematopoietic differentiation and contributes to leukemogenesis. Mol Cell Biol 23:8992-9002.
34. Ueda T, Watanabe-Fukunaga R, Fukuyama H, Nagata S, and Fukunaga R (2004) Mnk2 and Mnk1 are essential for constitutive and inducible phosphorylation of eukaryotic initiation factor 4E but not for cell growth or development. Mol Cell Biol 24:6539-6549.
35. van Prooijen R, van der Kleijn E, and Haanen C (1977) Pharmacokinetics of cytosine arabinoside in acute myeloid leukemia. Clin Pharmacol Ther 21:744-750.
36. Verma A, Mohindru M, Deb DK, Sassano A, Kambhampati S, Ravandi F, Minucci S, Kalvakolanu DV, and Platanias LC (2002) Activation of Rac1 and the p38 mitogen-activated protein kinase pathway in response to arsenic trioxide. J Biol Chem 277:44988-44995.
37. Waskiewicz AJ, Flynn A, Proud CG, and Cooper JA (1997) Mitogen-activated protein kinases activate the serine/threonine kinases Mnk1 and Mnk2. EMBO J 16:1909-1920.
38. Waskiewicz AJ, Johnson JC, Penn B, Mahalingam M, Kimball SR, and Cooper JA (1999) Phosphorylation of the cap-binding protein eukaryotic translation initiation factor 4E by protein kinase Mnk1 in vivo. Mol Cell Biol 19:1871-1880.
39. Wen J, Cheng HY, Feng Y, Rice L, Liu S, Mo A, Huang J, Zu Y, Ballon DJ, and Chang CC (2008) P38 MAPK inhibition enhancing ATO-induced cytotoxicity against multiple myeloma cells. Br J Haematol 140:169-180. (Pubitemid 350265041)
40. Wendel HG, De Stanchina E, Fridman JS, Malina A, Ray S, Kogan S, Cordon-Cardo C, Pelletier J, and Lowe SW (2004) Survival signalling by Akt and eIF4E in oncogenesis and cancer therapy. Nature 428:332-337. (Pubitemid 38418805)
41. Wendel HG, Silva RL, Malina A, Mills JR, Zhu H, Ueda T, Watanabe-Fukunaga R, Fukunaga R, Teruya-Feldstein J, Pelletier J, et al. (2007) Dissecting eIF4E action in tumorigenesis. Genes Dev 21:3232-3237.